Abstract: Endocannabinoids (eCBs) are endogenous lipid ligands that bind to cannabinoid receptors that also mediate the effects of marijuana. The eCB system is comprised of eCBs, anandamide, and 2-arachidonoyl glycerol, their cannabinoid-1 and cannabinoid-2 receptors (CB 1 and CB 2 , respectively), and the enzymes involved in their biosynthesis and degradation. It is present in both the central nervous system and peripheral organs including the kidney. The current review focuses on the role of the eCB system in normal kidney function and various diseases, such as diabetes and obesity, that directly contributes to the development of renal pathologies. Normally, activation of the CB 1 receptor regulates renal vascular hemodynamics and stimulates the transport of ions and proteins in different nephron compartments. In various mouse and rat models of obesity and type 1 and 2 diabetes mellitus, eCBs generated in various renal cells activate CB 1 receptors and contribute to the development of oxidative stress, inflammation, and renal fibrosis. These effects can be chronically ameliorated by CB 1 receptor blockers. In contrast, activation of the renal CB 2 receptors reduces the deleterious effects of these chronic diseases. Because the therapeutic potential of globally acting CB 1 receptor antagonists in these conditions is limited due to their neuropsychiatric adverse effects, the recent development of peripherally restricted CB 1 receptor antagonists may represent a novel pharmacological approach in treating renal diseases.
The endocannabinoid system
The recreational, psychoactive, and medicinal effects of marijuana, many of which have important therapeutic potentials, have been recognized for thousands of years [1] . Yet, it is only in the last several decades that our understanding of these effects had grown following some landmark discoveries in the field of cannabinoid research. To date, more than 60 plant-derived cannabinoid molecules have been identified in marijuana [2] , among which only Δ 9 -tetrahydrocannabinol (THC) is responsible for its psychoactive properties [3] . This initial discovery has allowed the synthesis of structurally modified molecules that have been used to study structure-activity relationships and reveal tight structural and steric selectivity in the biological actions of cannabinoids. Indeed, it took more than two decades to identify the THC binding site in the brain [4] , which was later cloned and named cannabinoid-1 (CB 1 ) receptor [5] . In addition to the brain-type CB 1 receptor, a second cannabinoid receptor was identified in lymphoid tissue and was named CB 2 [6] . Both CB 1 and CB 2 receptors, which share a low level (44%) of sequence homology [6] , are G protein-coupled receptors that mainly signal via G i /G o proteins, even though they may also activate G s , G q/11 , and G protein-independent signaling pathways [7] . These receptors are expressed in the brain [8] [9] [10] , liver [11, 12] , skeleton [13, 14] , kidney [15] , and many other tissues (reviewed in [16] ).
The existence of specific receptors for plant-derived molecules in mammalian cells initiated a search for specific endogenous ligands. Thus far, two extensively characterized endocannabinoids (eCBs) have been identified. The first was arachidonoyl ethanolamide (AEA, anandamide) [17] , and 2-arachidonoyl glycerol (2-AG) was identified 3 years later [18, 19] . Both AEA and 2-AG are generated "on demand" from membrane phospholipid precursors in response to elevated intracellular calcium or metabotropic receptor activation [20] . Their biosynthesis may proceed along multiple parallel pathways [21, 22] , which would make blocking their endogenous generation difficult. Unlike classical neurotransmitters, eCBs are not stored in vesicles, and the mechanism of their release from cells is not yet clear. Even when released, they remain largely membrane associated due to their hydrophobic nature and can be taken up by cells via a high-affinity uptake mechanism [23] , which is followed by their enzymatic degradation. AEA is primarily catabolized by the membrane-associated fatty-acid amide hydrolase (FAAH) [24] , whereas 2-AG is favorably degraded by monoglyceride lipase [25] . The CB 1 and CB 2 receptors, the eCBs, and enzymes/proteins involved in their biosynthesis, transport, and degradation jointly make up the "eCB system".
The renal eCB system
The introduction of potent and selective activators and inhibitors of CB 1 [26] and CB 2 receptors [27] and the generation of mouse strains deficient in these receptors [28] [29] [30] have been key tools for uncovering the biological functions of the eCB system. The presence and functional importance of the renal eCB system was initially reported by Deutsch and Chin [31] , who documented enzymatic activity that catalyzes AEA formation in crude rat kidney homogenates. Two years later, transcripts for the CB 1 receptor were identified in human kidney [32] . Several recent reports (Table 1) have documented the presence of functional CB 1 receptor in the entire kidney [15, [33] [34] [35] [36] [37] [38] [40] [41] [42] , including different parts of the nephron such as afferent and efferent arterioles [39] , glomeruli [33, 38, 40, 42, 43] , tubules [15] , the loop of Henle [44] , and collecting ducts [15] . It is also expressed in various subtypes of kidney cells such as podocytes [33, 41, 43, 45, 46] , proximal and distal tubular epithelial cells [15, 34, 37, 38, 40, 41, [47] [48] [49] , and mesangial cells [50, 54] . Moreover, CB 1 receptors are expressed in human clear-and chromophobe-renal cell carcinomas, as well as in renal oncocytoma [55, 56] .
Unlike CB 1 receptors, there is still controversy regarding the expression of CB 2 receptors in the kidney (Table 1) . While several groups were unable to detect its gene and protein expression in human and rat renal tissues [15, 44] , others reported that CB 2 receptors are expressed in human and rat renal cortex samples, with abundant expression in podocytes [51] , proximal tubule cells [34, 52, 53] , and rat mesangial cells [54] .
The kidney is also unique in its high basal levels of eCBs and activities of their biosynthesis and degrading enzymes [35, 38, 54, [57] [58] [59] [60] . While the kidney cortex has similar levels of AEA and 2-AG, its medulla has more than twofold higher levels of AEA than 2-AG [60] . In agreement with these findings, the low expression levels of FAAH in the medullary cells, which is also expressed at normal levels in the glomerulus, proximal and distal tubule cells, and collecting ducts, could explain its enrichment in this renal compartment [60] . In fact, cultured renal mesangial and endothelial cells contain low levels of AEA and are able to synthesize AEA from arachidonic acid and ethanolamine and to catabolize it by amidase activity [54] . Sampaio et al. [49] documented expression of the main enzymes responsible for eCB synthesis and degradation in immortalized epithelial cells derived from pig kidney [54] proximal tubule, the LLC-PK1 cell line. The functional relevance of the renal eCB system is illustrated by recent findings that implicate it in the regulation of renal hemodynamics, inflammation, and fibrogenesis, as well as in the dysregulation of these functions in pathologic states such as diabetic nephropathy (DN) and obesity-induced renal dysfunction. This will be discussed in more detail in subsequent sections.
eCBs and renal hemodynamics and function
A well-known feature of AEA is that it vasodilates arteries and arterioles via the CB 1 receptor (review in [61] ). In view of the presence of AEA, its degrading enzyme FAAH, and the CB 1 receptor in the kidney [31] , Deutsch et al. [54] demonstrated the existence of these three elements in cultured renal endothelial and mesangial cells in kidney homogenates. Moreover, exogenously administered AEA has the ability to (i) vasodilate juxtamedullary afferent arterioles and (ii) stimulate the release of nitric oxide by renal endothelial cells, suggesting a key role for the eCB system in regulating renal hemodynamics. More specifically, AEA, via activation of CB 1 receptors present in both afferent and efferent arterioles, increases renal blood flow and decreases the glomerular filtration rate (GFR), effects that are completely blocked by the CB 1 receptor antagonists AM281 and AM251. These findings are independent of its effects on blood pressure and the sodium excretion rate [39] . Using a methylated analog of AEA, methanandamide, Li and Wang [62] showed that its intrarenal medullary infusion to anesthetized rats increases urine flow rate without changing sodium excretion and decreases mean arterial blood pressure, suggesting a regulation of body volume homeostasis and blood pressure by the renal eCB system. In a follow-up study in which the renal excretory effect of AEA was tested following its infusion into the renal medulla, it was found that this effect is probably mediated via cyclooxygenase-2 (COX-2). Briefly, AEA or one of its COX-2 metabolites, prostamide E2, shares similar properties with the vasodepressor lipid ligand medullipin, leading to increased renal blood flow, vasorelaxation, and urinary sodium excretion [60] . In regard to the specific effect of AEA on tubular sodium transport, a recent study demonstrated that AEA regulates sodium transport at the level of the medullary thick ascending limb in the kidney. In this segment, AEA (via the CB 1 receptor) stimulates the production of nitric oxide, which blocks the apical Na + /H + transporter and Na
suggesting an additional activity of AEA as a diuretic agent. Another important sodium transporter that maintains extracellular fluid volume and composition is the Na + /K + -ATPase pump located in proximal tubule cells. Recently, its activity was shown to be modulated by the CB 1 /CB 2 agonist WIN55,212-2 and the CB 1 receptor peptide agonist hemopressin. While the WIN55,212-2 stimulatory effect is mediated by protein kinase C, hemopressin increases cyclic adenosine monophosphate and stimulates protein kinase A activity [49] . Collectively, these findings highlight the importance of the eCB system in mediating renal hemodynamics and function.
eCBs and DN
Diabetes mellitus (DM), a chronic disease that is now reaching epidemic proportions, has been described as a catalyst for a number of conditions, most notably cardiovascular disease, retinal disease, and chronic kidney disease (CKD). Also termed DN, CKD is manifested by glomerular hypertrophy and transient hyperfiltration that lead to albuminuria, renal fibrosis, and ultimately a progressive decline in GFR [63] . In agreement with the observation that the CB 1 and CB 2 receptors are expressed in the kidney, several groups have tested the hypothesis of a direct signaling effect via these receptors on podocytes and mesangial and tubular cells, as well as their ability to mediate the deleterious consequences of DN.
Role of CB 1 receptors in DN
The first direct indication for CB 1 receptor involvement in DN came from a clinically relevant model of DN induced by the chemotherapeutic drug cisplatin [35] . While cisplatin-induced DN does not alter CB 1 receptor gene or protein expression, it increases renal levels of AEA but not 2-AG. Either genetic deletion or pharmacological blockade of the CB 1 receptor attenuates cisplatin-induced renal dysfunction. The reductions in oxidative/nitrosative stress, cell death, and infiltration of inflammatory cells within the kidney in cisplatin-treated CB 1 −/− mice and wild-type animals treated with the selective CB 1 receptor antagonists AM281 or SR141716 are likely mediated through attenuation of the overactivated p38-mitogen-activated protein kinase signaling pathway [35] .
More definitive proofs for the direct contribution of the CB 1 receptor to DN arose independently from murine models for type 1 and type 2 DM. In the first model induced by streptozotocin (STZ), kidney expression of the CB 1 receptor is enhanced in both diabetic mice [33] and rats [37] . More specifically, colocalization of the CB 1 receptor with nephrin points to their predominant expression in podocytes. Moreover, pharmacological inhibition of the CB 1 receptor by AM251 ameliorates STZ-induced albuminuria and prevents the downregulation of podocyte proteins implicated in the maintenance of glomerular permselectivity to proteins [33] . Because proteinuria is an independent predictor of renal outcome in patients with type 1 DM [64] , a recent study tested the specific role of CB 1 receptors in mediating urinary protein excretion. Using a genetic CB 1 activation mouse model and pharmacological stimulation of CB 1 in rats, Hsu et al. [65] showed that CB 1 receptor activation/stimulation increases urinary protein levels and is associated with enhanced glomerular CB 1 and vascular endothelial growth factor (VEGF) expression levels, as well as a subsequent reduction in nephrin gene and protein expression levels, suggesting a CB 1 /VEGFdependent signaling pathway that may lead to podocyte dysfunction and proteinuria.
Considering that type 2 DM may also lead to renal dysfunction, a study by Buraczynska et al. [66] recently reported a significant association between a CB 1 receptor gene polymorphism (G1359A) and DN in patients with type 2 DM. To date, two murine models for type 2 DM have been utilized to test the involvement of CB 1 receptor in DN. Using the diabetic db/db mouse model, Nam et al. [43] documented preferentially increased CB 1 receptor expression in glomerular podocytes and demonstrated that SR141716 treatment significantly inhibits the expression of profibrotic and proinflammatory molecules in the diabetic kidney. Insights into the mechanism by which the CB 1 receptor modulates podocyte injury in type 2 DM were found in a recent report by Jourdan et al. [41] , who used the well-established Zucker diabetic fatty (ZDF) rat model. Chronic (3 months) in vivo treatment of ZDF rats with the novel peripherally restricted CB 1 receptor antagonist, JD5037 [48] , completely prevents renal pathologies related to glomerular dysfunction, which are strongly correlated with the specific expression of CB 1 receptors in podocytes and the expression of renal oxidative/nitrative stress markers [41] . These findings highlight the therapeutic potential of such peripheral compounds in DN, especially since the development and clinical testing of globally acting CB 1 receptor antagonists such as SR141716 has been halted due to neuropsychiatric side effects [67] .
Additional mechanistic insights into how CB 1 receptor activation influences DN is provided by in vitro studies testing the effects of high glucose (HG), high albumin (HA), and increased palmitic acid (PA) levels on different types of kidney cells including podocytes, proximal tubular cells, and mesangial cells. Several lines of evidence show that HG stimulation of podocytes significantly increases CB 1 receptor expression [41, 43, 45] . This elevation is associated with increased expression of collagen type IV, plasminogen activator inhibitor-1, and sterol regulatory element-binding transcription factor-1, and all of these effects are completely blocked by SR141716 and siRNA for the CB 1 receptor [43] . The relationship between the effect of HG and CB 1 receptor stimulation in podocytes has been tested by exposing cells to either 30 mM glucose or 5 μM arachidonyl-2′-chloroethylamide (a CB 1 receptor agonist). Both stimuli increase CB 1 receptor expression and decrease podocin and nephrin expressions, effects that are prevented by JD5037 and siRNA-mediated knockdown of podocyte CB 1 receptor [41] . Likewise, downregulation of podocyte CB 1 receptor expression or pharmacological blockade by AM251 prevents HG-induced Akt phosphorylation, endoplasmic reticulum (ER) stress-related protein expression, and phosphorylation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) [45] . Moreover, a recent study suggests that HG-induced podocyte injury is mediated by a coactivator-associated arginine methyltransferase 1-AMP-activated protein kinase alpha and the CB 1 receptor signaling pathway [46] . Taken together, these findings highlight the significant role of the CB 1 receptor in mediating HG-induced podocyte dysfunction.
Other factors besides HG may affect podocyte function and lead to DN, one of which is the renin-angiotensin system [68] . Indeed, its important role in regulating CB 1 receptor-induced DN is supported by recent findings that angiotensin II, acting via the type 1 angiotensin II receptor, induces increased CB 1 receptor signaling in podocytes, an effect that is completely reversed by treatment with the angiotensin II receptor antagonist losartan [41] . Given evidence for CB 1 receptor and type 1 angiotensin II receptor heterodimerization, which amplifies the activity of the latter receptor [69] , the proposed mechanism could provide novel insight into the pathologic pathways governing DN development in normoglycemic conditions.
The effects of HG and HA were recently tested in another cell type within the kidney, the proximal tubules. In this work, Jenkin et al. [37] demonstrated that while HG alone does not affect CB 1 receptor expression, combined HG and HA treatment of HK2 proximal tubule cells significantly increases its expression. The functional role of CB 1 receptors within these cells is further demonstrated by findings that CB 1 receptor activation with AEA leads to hypertrophy, while its blockade with AM251 in the presence of AEA reduces this effect in HK2 cells [34] . An important modulator of renal tubular damage in DN is elevated levels of PA, which is known to activate inflammatory, ER stress, and apoptosis pathways in renal proximal tubule cells [70, 71] . In fact, PA upregulates CB 1 receptor mRNA and protein expressions and promotes the receptors internalization in these cells. Furthermore, PA-induced activation of CB 1 receptor decreases cell proliferation and induces apoptosis by inducing the ER stress response, effects that are completely antagonized by either pharmacological blockade of CB 1 receptor or siRNA knockdown [47] .
A similar observation for increased CB 1 receptor expression and its cellular internalization was recently reported in primary rat mesangial cells exposed to HG conditions [50] . The effect of HG on these cells induces apoptosis via NF-κB and phospholipase A 2 stimulation, which, in turn, reduces expression of the ER stress chaperone GRP78 and increases levels of p-PERK, p-eIF2α, pAFT4, and CHOP [50] . These ER stress proteins have been also linked to DN development in vivo [72] . A parallel signaling pathway via Ras, ERK, and peroxisome proliferator-activated receptor gamma was recently suggested to modulate the HG-induced CB 1 receptor-mediated inflammation and fibrosis in mesangial cells [42] .
The specific role of the CB 1 receptor in the development of renal fibrosis was recently demonstrated in several human nephropathies and mice subjected to unilateral ureteral obstruction (UUO) [38] . In this mouse model, the CB 1 receptor was among the most significantly upregulated genes, especially in renal tubules and podocytes and also in interstitial myofibroblasts. High CB 1 receptor expression is also found in human nephropathies and correlates with kidney function. Moreover, genetic inactivation and pharmacological blockade by either globally acting or peripherally restricted CB 1 receptor antagonists dramatically ameliorates the development of renal fibrosis in mice during UUO [38] . This suggests that the CB 1 receptor plays an important role in renal fibrosis regardless of the initial renal injury.
Role of CB 2 receptor in DN
Unlike CB 1 , several lines of evidence show that the CB 2 receptor has a protective role in the diabetic kidney. Increased hypertrophy is observed in renal proximal tubule cells treated with the CB 2 inverse agonist AM630 [34] . In the same cells, reduced mRNA and protein levels of CB 2 receptor are measured following exposure to HA in the presence and absence of HG. These changes are likely mediated by internalization of albumin and are not regulated by ERK1/2 signaling [52] . While CB 2 receptor expression is unaffected in STZ-induced diabetic mice and rats [51, 52] , its glomerular expression is downregulated in patients with advanced DN [51] . This observation could be explained by increased intraglomerular pressure, but not renal hyperglycemia. Indeed, one study showed a substantial reduction in CB 2 receptor expression following exposure of cultured podocytes to mechanical stretch but not an HG milieu [73] . Chronic treatment of STZ-induced diabetic mice with the selective CB 2 agonist AM1241 ameliorates albuminuria and nephrin and zonula occludens-1 downregulation. Yet it does not affect glomerular hypertrophy or monocyte chemotactic protein 1 expression [51] . Likewise, CB 2 receptor deletion in STZ-treated mice exacerbates albuminuria, renal function, nephrin and podocin protein loss, and mesangial expansion [73] . Unlike a previous study by the same group, global deletion but not pharmacological CB 2 receptor activation regulates renal fibrosis. In their earlier study, Barutta et al. [51] demonstrated that AM1241 does not ameliorate renal fibrosis, while their recent findings show that the expressions of fibronectin, type I collagen, and type IV α4 chain collagen are further enhanced in CB 2 -null diabetic mice [73] , suggesting that pharmacological modulation of CB 2 receptor by AM1241 is not sufficient to protect against renal fibrosis. To clarify how monocyte infiltration could be a potential mediator in the genetic absence of CB 2 receptor and indirectly affects kidney function by releasing cytokines and reactive oxygen species (ROS), it is found that transplantation of CB 2 -null bone marrow cells does not magnify albuminuria, renal dysfunction, and/or fibrosis in STZtreated wild-type animals [73] .
In a similar in vivo mouse model of nephropathy, Mukhopadhyay et al. [74] found that treatment of mice with the CB 2 receptor agonist HU-308 attenuates cisplatin-induced DN, which is associated with increased chemokine production, inflammatory cell infiltration in the kidney, and the consequent release of ROS and inflammatory mediators that lead to tubular cell apoptosis [74] . In a follow-up study, Horváth et al. [75] tested the therapeutic effect of (E)-β-caryophyllene (BCP) in cisplatin-induced DN. BCP, which is a compound found in many essential oils of spices and a natural CB 2 agonist [76] , can markedly attenuate cisplatin-induced decline in kidney function and ameliorate the observed histological damage. Its protective effect is completely abolished in CB 2 receptor knockout mice, demonstrating that it is mediated through CB 2 receptors. Taken together, these preclinical findings suggest that targeting CB 2 cannabinoid receptors may represent a novel protective strategy against DN.
eCBs and obesity-related kidney dysfunction
Recently, increasing attention has been paid to obesityassociated renal structural and functional changes that develop early in the course of obesity and metabolic syndrome [77] [78] [79] . In fact, obese individuals have a threefold greater risk of developing end-stage renal disease (ESRD) than non-obese individuals [80] . Even in the absence of DM and hypertension, which account for > 70% of ESRD [81, 82] , obesity induces hemodynamic and morphological changes in the kidney (e.g. glomerular hypertrophy, glomerular basement membrane thickening, mesangial matrix expansion, and increased tubular inflammation) [83, 84] . Together with renal inflammation [85] and oxidative stress [86] , these changes may lead to decreased renal function and ultimately glomerulosclerosis and tubulointerstitial fibrosis [78, [87] [88] [89] .
Several lines of evidence indicate that overstimulation of the eCB system via the CB 1 receptor contributes to the pathogeneses of obesity and metabolic syndrome. By activating CB 1 receptors in the brain, eCBs produce marijuana-like effects including an increase in appetite (the "munchies") and lipogenesis [90, 91] . CB 1 receptornull mice are resistant to diet-induced obesity (DIO), hepatic steatosis, and the associated hormonal/metabolic changes, even though their caloric intake is similar to that of wild-type mice [11, 92] . As the kidney is a major source of eCBs and contains the CB 1 receptor, the possible role of the eCB system in regulating obesity-related kidney dysfunction has been explored in several studies. Long-term treatment of obese fa/fa Zucker rats (a strain that is characterized by hyperphagia and obesity due to a mutation in the leptin receptor-encoding gene) with the CB 1 receptor antagonist SR141716 ameliorates chronic renal failure [40] . Moreover, the authors showed that chronic SR141716 administration significantly delays the development of proteinuria, improves creatinine clearance, and decreases the severities of glomerular and tubulointerstitial lesions and renal hypertrophy [40] . Measurements of kidney eCB levels in DIO mice reveals a significant increase in AEA levels, which could suggest an elevated eCB "tone" that may directly affect renal function via the CB 1 receptor [58] . Likewise, increased CB 1 receptor expression was found in DIO rats, and chronic blockade of CB 1 receptors by AM251 reverses obesity-induced tubular hypertrophy, albuminuria, and plasma creatinine levels [36] .
A major feature of DIO is leptin resistance, probably induced by hyperleptinemia [93] due to increased leptin production by adipocytes and its reduced clearance by the kidney. The latter mechanism involves the renal proximal tubule cells, in which leptin is metabolically degraded following its uptake by the multifunctional endocytic receptor megalin [94] . In a recent study, the CB 1 receptor was shown to regulate megalin expression and leptin uptake and degradation. First, the renal megalin expression is reduced by obesity in wild-type but not CB 1 receptor-null mice, and peripherally restricted CB 1 receptor blockade by JD5037 reverses the obesity-induced decline in megalin mRNA and protein expression levels in DIO mice. Second, blockade of CB 1 receptor in cultured renal proximal tubule cells increases megalin expression and leptin uptake and degradation [48] . Because megalin mediates albumin uptake in renal proximal tubule cells [95] , impaired megalin expression and/or activity may result in albuminuria. In accordance with the in vivo study published by Tam et al. [48] , recent findings demonstrate that elevated leptin levels, which regulate transforming growth factorbeta expression in the renal proximal tubule cells, reduce albumin handling by these cells via altered megalin expression and function [96] . On the other hand, the same group reported increased megalin expression in a DIO rat model and no significant alteration in its expression levels following AM251 treatment [36] , suggesting that other mechanisms (e.g. hyperglycemia) might contribute to the regulation of megalin. Collectively, these findings highlight the therapeutic potential of targeting the CB 1 receptor in obesity-induced renal dysfunction.
As per the role of the CB 2 receptor in this phenomenon, recent work by Jenkin et al. [53] determined the renal effect of CB 2 receptor agonism and antagonism in DIO rats. Stimulation of CB 2 receptors with AM1241 ameliorates the progression of obesity-related kidney dysfunction as measured by urinary protein and renal sodium excretion rates, while antagonism of CB 2 receptors with AM630 reduces creatinine clearance, indicating enhanced renal failure.
Concluding remarks
The eCB system is present in the kidney where it is involved in controlling various renal functions with important therapeutic implications. Increased CB 1 receptor activity contributes to kidney hemodynamic abnormalities and dysfunction, whereas CB 1 receptor blockade may attenuate and delay these changes. eCBs acting via CB 1 receptors in podocytes, proximal tubule cells, and mesangial cells have emerged as mediators of both DN and obesity-associated renal dysfunction. This provides strong evidence for the therapeutic use of CB 1 receptor antagonists in these conditions. Although adverse neuropsychiatric effects limit the therapeutic potential of centrally acting CB 1 receptor antagonists, the recent development of second-generation, peripherally restricted CB 1 receptor antagonists may alleviate these problems. Additionally, non-psychoactive CB 2 receptor agonists may offer therapeutic benefit in attenuating kidney injury and promoting tissue repair in DN-and obesity-induced renal damage.
